𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An unusual genotype in an Ashkenazi Jewish patient with Tay-Sachs disease

✍ Scribed by Shirah Shore; Jerzy Tomczak; Eugene E. Grebner; Rachel Myerowitz


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
438 KB
Volume
1
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis


Communicated by Robert J. Desnick

The Ashkenazi Jewish population is enriched for carriers of a fatal form of Tay-Sachs disease, a recessive inherited disorder caused by mutations in the a-chain of the lysosomal enzyme P-hexosaminidase A. Approximately 20% of the Ashkenazi carriers harbor a splice junction defect while about 78% bear a 4 base pair (bp) insertion. However, the Ashkenazi Jewish patient used in the original description of the 4 bp insertion carried this lesion in only 1 allele and was negative for the splice junction mutation. We cloned the insertion negative allele and by sequence analysis of the exons found a point mutation in exon 11 that results in substitution of Trp392 with a premature termination codon. Nine Ashkenazi Jewish carriers that tested negative for the major and minor mutations as well as for a lesion causing an adult form of Tay-Sachs disease did not carry the base change defect, suggesting that it may be a recent and/or rare mutation. This finding also indicates that screening the Ashkenazi population solely by recombinant DNA methods for the splice junction, 4 bp insertion, and adult mutations may result in occasional false negatives.


πŸ“œ SIMILAR VOLUMES


Idiopathic immune-mediated acquired von
✍ Alhumood, Salah A.; Devine, Dana V.; Lawson, Laurie; Nantel, Stephen H.; Carter, πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 42 KB πŸ‘ 2 views

A case of idiopathic immune-mediated von Willebrand's disease (AvWD) associated angiodysplasia and recurrent lower gastrointestinal bleeding is reported. Coagulation parameters at presentation were activated partial thromboplastin time of 41 sec, bleeding time >15 min, factor VIII procoagulant activ